Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer

ABSTRACT: To estimate the effect of KRAS mutation status (Wild-type versus Mutant) on objective response rate and other measures of efficacy for patients treated with panitumumab in combination with a chemotherapy regimen of irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line therapy for metastatic colorectal cancer (mCRC).

DISEASE(S): Metastatic Colorectal Cancer,Patients With Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2042621 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR